STAAR Surgical Files 8-K for Regulatory Disclosure
Ticker: STAA · Form: 8-K · Filed: Jan 13, 2025 · CIK: 718937
| Field | Detail |
|---|---|
| Company | Staar Surgical Co (STAA) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
STAAR Surgical filed a standard 8-K, no new material news.
AI Summary
STAAR Surgical Company filed an 8-K on January 13, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This filing serves as a routine update for investors, confirming the company's adherence to regulatory reporting standards without disclosing new material information.
Risk Assessment
Risk Level: low — The filing is a routine regulatory disclosure and does not contain any new material information that would impact the company's risk profile.
Key Players & Entities
- STAAR Surgical Co (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- January 13, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits, as required by the SEC.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is January 13, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 25510 Commercentre Drive, Lake Forest, California 92630.
What is the company's telephone number?
The company's telephone number, including area code, is 626-303-7902.
Does this filing announce any new material events or financial results?
Based on the provided text, this filing appears to be a routine regulatory disclosure and does not explicitly announce any new material events or specific financial results.
Filing Stats: 563 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-01-13 07:03:40
Filing Documents
- staa-20250113.htm (8-K) — 45KB
- staa-ex99_1.htm (EX-99.1) — 14KB
- img177331332_0.jpg (GRAPHIC) — 11KB
- 0000950170-25-004553.txt ( ) — 193KB
- staa-20250113.xsd (EX-101.SCH) — 29KB
- staa-20250113_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 13, 2025, STAAR Surgical Company (the "Company") issued a press release (the "Press Release") regarding its plans to release its financial results for the fourth quarter and fiscal year ended December 27, 2024 on or about Wednesday, February 19 after the market close. The Press Release also included commentary regarding the Company's sales growth, as well as market dynamics in China. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by this reference. The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report, and Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release of the Company dated January 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STAAR Surgical Company January 13, 2025 By: /s/ Tom Frinzi Thomas Frinzi President and Chief Executive Officer